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Abstract
The largest burden of hepatocellular carcinoma (HCC) lies in Asia, secondary to hepatitis B virus (HBV) infection.
Improved survival with sorafenib has fostered new research but many challenges remain in designing clinical trials.
The disease, its management, and populations affected by it are heterogeneous worldwide and within Asia. An
expert conference of Eastern Asian oncologists and hepatologists was convened to foster consensus in clinical trial
design. The panel identified key areas that need to be addressed to facilitate clinical trials in Asia. Stratification by
viral etiology is desirable within Asia and by region in global trials. Antiviral therapy should also be considered as a
stratification factor and incorporated into HCC management in trials. The panel agreed that histological diagnosis is
not required for trial entry and that Barcelona-Clinic Liver Cancer (BCLC) staging is acceptable for trials as long as
portal hypertension can be better defined with standardized methodology. Consensus in treatment must be
sought to allow multi-national trials and it must be recognized that first-line sorafenib is not largely feasible in Asia.
Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new
treatment options in this challenging disease.
Background
Over 600,000 cases of hepatocellular carcinoma (HCC)
are diagnosed annually worldwide and the mortality-to-
incidence rate ratio is second only to pancreatic cancer
[1,2]. The incidence of HCC varies widely by geographi-
cal region. Asia carries the largest burden with 55% of
all cases occurring in China [1]. Age-standardized inci-
dence rates per 100,000 persons for men are 45.0 in
Korea (1999-2001) [3], 37.9 in China (2002) [1], and
23.1 in Japan (2002) [1]. Corresponding rates for women
are 12.0, 14.2, and 7.6. Globally, the predominant cause
of HCC is viral infection with hepatitis B virus (HBV) or
hepatitis C virus (HCV) [4].
Hepatocellular carcinoma is refractory to cytotoxic
chemotherapy [5] and the failure of cytotoxic regimens
has led to a bleak outlook. However, the recent develop-
ment of molecular targeted therapies is changing the
landscape and offering hope. Researchers have found
new optimism for initiating clinical trials after sorafenib
showed efficacy in advanced disease [6]. Currently, trials
are planned or ongoing in all stages of HCC; however,
many issues remain [7]. Most salient is the variability in
management practices both between Asia and the West
and within Asia. Key differences are apparent in the
etiology, diagnosis, staging, and treatment of HCC
among countries. These differences complicate the con-
duct of international clinical trials that will foster
approval and availability of new therapeutic entities.
In order to forge a better understanding of how HCC
clinical practices in the Eastern Asian region compare to
current global clinical trial requirements, an expert con-
ference was held. Participants of the panel (the authors)
are oncologists and hepatologists representing China,
Hong Kong, Japan, Korea, and Taiwan who have an
expertise in treating HCC. Each panelist offered insight,
reviewed herein, about how HCC is managed across
Eastern Asia and how management practices and clinical
trial requirements can be unified to advance new treat-
ments, particularly targeted agents, for HCC.
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Viral etiology varies by region with HBV predominating
in non-Japanese Asians and accounting for approxi-
mately 70-80% of cases. In Japan, most of Europe, and
in the United States, HCV is more common than HBV
among viral etiologies [3,8-11]. However, in the United
States, 67% of HCC cases are seronegative for both
viruses [10].
The increased incidence of HBV-HCC in Eastern Asia
compared to Japan and Western nations leads to differ-
ent management issues and prognosis that affect clinical
trial design. Hepatitis C virus-HCC is more likely to
develop in the background of cirrhosis than HBV-HCC
[12]. Therefore, the underlying liver disease may differ
in HCC patients by region, a factor that weighs heavily
in treatment decisions.
Survival differences have been observed according to
geographic region and viral etiology, though the reasons
for these observations remain unclear. In clinical trials
of systemic therapy for advanced HCC, trials done in
Asian countries reported inferior survival compared
with trials done in non-Asian countries [13]. Possible
reasons include variation in genetic and/or epigenetic
aberrations between different viral etiologies and the
propensity for Asian physicians to use local therapy
more aggressively and in later stages, resulting in enroll-
ment of a more advanced patient population to trials of
systemic therapy. Survival between HBV-HCC and
HCV-HCC appears similar in early-stage, resectable
HCC, if staging and other clinical parameters are con-
sidered [14]. However, two retrospective studies have
found poorer survival in HBV-HCC among patients
with unresectable, advanced disease [15,16]. Attributing
the survival difference to viral etiology alone is difficult
but demonstrates the need for considering the potential
differences in clinical trials.
Additionally, in contrast to HCV, HBV reactivates
with immune suppression, complicating treatment with
immunosuppressive regimens [17,18]. The predomi-
nance of HBV-HCC in Asia is associated with increased
use of antiviral agents to prevent viral reactivation dur-
ing HCC treatment. Antiviral therapy with lamivudine
has reduced the incidences of HBV reactivation and
hepatitis, reduced the severity of hepatitis episodes, led
to fewer disruptions in chemotherapy, and reduced mor-
tality related to HBV reactivation in clinical trials of
patients with HCC or other cancers who are receiving
chemotherapy [19-22]. Anti-viral therapy following cura-
tive resection, radiofrequency ablation, or other local,
non-chemotherapeutic treatments for HBV-HCC, has
been shown to increase residual liver volume and/or
function and may prolong survival [23-25]. Furthermore,
interferon, given after curative therapy, may increase
recurrence-free survival rates [26,27]. These benefits
indicate that use of antiviral therapy is an important
confounding factor in HCC clinical trials.
A separate international expert panel has recom-
mended stratification according to region for global
trials but discouraged further stratification according to
etiology [7]. However, in light of the confounding fac-
tors described herein, the current panel agreed that
trials within Eastern Asia should include stratification by
HBV or HCV etiology. Further, antiviral therapy should
be both considered as a stratification factor and incor-
porated into the overall management of patients in
international HCC clinical trials.
Screening
Stage at diagnosis differs both within Eastern Asia and
between Eastern Asia and Western nations. Using
TNM-based staging systems, China and Japan have rela-
tively high proportion of patients diagnosed at Stage I
or II compared to Hong Kong and Korea. In the United
States, a higher percentage of patients are diagnosed
with distant metastasis compared to Asian countries
[28,29].
T h ed i f f e r e n c e sm a yr e f l e c tvariable screening prac-
tices. The proportion of patients who receive screening
in the United States appears to vary according to the
individual’s healthcare. Only 25% of family practice phy-
sicians report routinely screening appropriate patients
for HCC compared to 84% of physicians who are mem-
bers of the Association for the Study of Liver Diseases
(AASLD) [30,31]. In a study of 157 patients diagnosed
with HCC at three US Veteran Affairs (VA) medical
centers, 39% of patients with a known risk factor for
HCC received screening [32]. With the exception of
Hong Kong, where screening has been conducted in the
context of study, screening high-risk populations is the
standard of care in Asia. With diagnosis occurring at
earlier stages, Eastern Asian countries are better able to
utilize curative therapies, significantly affecting treat-
ment paradigms and clinical trial populations.
Diagnosis
Both pathological and clinical diagnostic procedures
vary according to country. The majority of pathological
diagnoses are made by core biopsy in Korea, China, and
H o n gK o n g ,w i t hf i n en e e d l ea s p i r a t i o n( F N A )u s e d
infrequently. In contrast, 30% or fewer of pathological
diagnoses are made by core biopsy in Japan, and Tai-
wan. Taiwan employs FNA in approximately 10% of
cases but utilizes surgery for pathologic diagnosis in
approximately 38% of cases. Protocols designating
biopsy-proven HCC as an enrollment requirement
would conflict with current practices in Japan and
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the advanced/metastatic setting, histological confirma-
tion of HCC is not necessary. Further, pre-treatment
biopsy may result in tumor seeding which would com-
plicate neoadjuvant trials.
Staging
A variety of staging systems are employed worldwide
[33-36]. Several of these systems are based on the
tumor-node-metastasis (TNM) paradigm or incorporate
TNM groupings as a variable [33-35,37]. Other systems,
such as the Barcelona-Clinic Liver Cancer (BCLC) sta-
ging system, incorporate measures of liver function and
underlying disease. Complicating international clinical
trial design is the variable use of these systems both
within Asia and globally. Each region of Asia repre-
sented by the panel currently utilizes a different system.
In China, the revised Staging Criteria of Primary Liver
Cancer is used. This system was developed by the Chi-
nese Society of Liver Cancer. The system uses criteria
based on size, number and location of tumors, lymph
node spread, extrahepatic metastasis, portal vein throm-
bosis, and liver function (Child-Pugh scores) [38]. In
Japan, both the staging system and treatment algorithm
apply liver function as the first category of evaluation
rather than tumor size. Hong Kong does not have a uni-
fied staging system. Although BCLC is considered a
valuable tool for a treatment algorithm in Hong Kong,
the system is considered less useful for prognostication.
The Chinese University Prognostic Index (CUPI) [37]
has been found useful for prognostication at one center
due to the more advanced population [39]. Korea
employs a modified International Union Against Cancer
(UICC) system and Taiwan uses BCLC.
The TNM-based staging systems have an important
drawback: these systems do not account for underlying
liver disease [40]. In HCC, the presence of liver disease
is a common and important prognostic factor that is
integral in determining treatment [40,41]. For these rea-
sons, TNM-based systems have limited value in the
comprehensive management of HCC. The Child-Pugh
(CP) score is a widely-accepted system to evaluate liver
function. Despite empirical selection of variables, this
tool represents a simple, bedside tool that predicts mor-
tality in cirrhotic patients with a degree of accuracy not
substantially less than the more statistically sound
model for end-stage liver disease (MELD) [42]. The
BCLC staging system incorporates measures of liver
function (portal hypertension, bilirubin, and CP scores
at higher stages) and has emerged as the standard for
clinical trial design [6,43]. However, this system is not
generally used in Eastern Asia with the exception of
Taiwan. China, specifically, has failed to adopt this sys-
tem due to the omission of portal vein thrombosis as a
factor, which has been shown to independently predict
mortality [41]. Additionally, BCLC includes portal
venous hypertension which requires an invasive proce-
dure to measure that is not standard practice in Asia.
However, the panel indicated that, if required for clinical
trials seeking United States Food and Drug Administra-
tion approval, BCLC would be acceptable if the
protocols also incorporated portal vein hypertension -
measured and defined with non-invasive standardized
methodology - and further evaluation of liver function.
Treatment Practices
Treatment practices vary somewhat throughout Eastern
Asia and no unified treatment algorithm exists. Japan,
China, Hong Kong, Korea, and Taiwan each use sepa-
rate treatment algorithms, all of which differ from the
BCLC treatment algorithm [7,44,45]. Such variations in
treatment practices cause challenges in defining treat-
ment protocols for international clinical trials.
Potentially Curative Treatment Options
Resection is utilized more often in Eastern Asia versus
Western nations, which may reflect diagnosis at earlier
stages and less cirrhosis in Asia [46]. In some centres in
China, Taiwan, and Japan, between 34-40% of patients
undergo resection, while the proportion is approxi-
mately 10-20% in others. In parts of East Asia [47,48],
patients with recurrence undergo re-resection. Local
ablation is performed in approximately 15% of patients
in China, Hong Kong, and Taiwan and approximately
30% of patients in Japan. Liver transplant is the only
treatment modality that offers a cure both for HCC and
the underlying liver disease, but its application is limited
both in Eastern Asia and the West.
Nonsurgical Local Treatments
Although TACE and transarterial embolization (TAE)
are standards of care, significant heterogeneity exists
among countries and institutions with respect to the
types of embolizing materials and techniques utilized.
Embolizing materials used typically include a mixture of
iodized oil (lipiodol) and an anthracycline (epirubicin or
doxorubicin) or cisplatin followed by gelatin sponge par-
ticles (Japan, Taiwan, Hong Kong). Nonetheless, other
agents are used, particularly in China where 5-fluoroura-
cil (5-FU) and mitomycin-C may be employed. Japan
uses HAI with cisplatin alone, 5-FU and cisplatin (FP),
or 5-FU and interferon. Currently, no consensus has
been reached regarding the interval between procedures
or endpoints. Other local therapies are variably utilized
and include intratumoral injection, laser therapy,
cryotherapy, microwave coagulation therapy, hepatic
arterial infusion (HAI), intraarterial radiotherapy with
yttrium-90 and conformal external radiotherapy.
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Targeted therapy has been employed only for advanced
disease [7,44,45]. A multitude of targeted therapies have
been investigated for use in HCC; however, only sorafe-
nib is approved for use in Asian and Western countries.
These approvals were based on improved survival in the
SHARP trial and the parallel Asian phase III trial [6,49].
Although sorafenib has been approved in Asia, the
agent is not widely used largely due to cost [50]. Cost-
sharing programs have been started in some countries
to manage this issue. Such programs have been success-
ful in that they expand usage; however, lack of long-
term coverage renders the practice unsustainable.
In addition to cost, emerging evidence suggests that
sorafenib may be less well tolerated by Asian patients
compared to Western patients. Hand-foot skin reaction
(HFSR) appears to be more frequent in Asians, particu-
larly lower-grade reactions. Hand-foot skin reaction (all
grades) occurred in 21% of patients in the US SHARP
study; the rate was 45% in the Asian phase III sorafenib
trial [6,46]. Grade 3 event rates were 8% in SHARP
compared with 11% in the Asian trial. Korean and Japa-
nese studies have reported rates of 56%-57% (all grades)
[51,52]. In the Korean population, HFSR was the most
common reason for treatment interruption. Indeed, dose
reductions for HFSR were more frequent in the Asian
phase III trial (11%) than in SHARP (5%) [6,46] The
panelists noted that in practice, dose reduction or use of
a reduced starting dose of sorafenib is common in Asia.
Lower dosing is being investigated in small Asian trials.
In a Japanese phase I study, sorafenib 200 mg twice
daily led to a 38% incidence of HFSR [52].
Though HFSR is most common, some differences
between Westerners and Asians may be present with
respect to the drug’s effect on the liver. The Korean
population experienced a 4% rate of grade 3 or 4 hyper-
bilirubinemia associated with marked ALT elevations
[51]. Individual differences in drug metabolism may be
present. Increased bilirubin was reported separately in a
patient with UGT1A1 polymorphism; the authors pro-
posed that sorafenib inhibition of UGT1A1 in this
patient may have contributed to the hyperbilirubinemia
[53].
Other Systemic Therapies
Systemic cytotoxic chemotherapy has failed to prolong
survival in advanced HCC [5]. Small studies of cytotoxic
chemotherapy plus biochemical modulation may achieve
tumor control in patients with good performance status
and liver function reserves and no hypersplenism
[54-56]. In Korea, chemotherapy is used as part of con-
current chemoradiotherapy protocols at some centers.
In Hong Kong, systemic cytotoxic chemotherapy is con-
sidered when a patient fails or is ineligible for anti-
VEGF therapy. Chemotherapy was not recommended in
Japanese treatment guidelines.
In China, use of traditional Chinese medicine (TCM)
is common and unique compared to Western nations.
These medicines can be categorized according to two
main purposes: 1) promoting liver health and delaying
cirrhosis and 2) countering the side effects of che-
motherapy. Panelists indicated that the first type of
TCM must be allowed in clinical trials; excluding these
treatments would severely restrict enrollment. However,
the second type of TCM could potentially be excluded if
required.
Investigational Targeted Therapy
Targeted agents are at the forefront of HCC clinical
research. Promoting clinical trial participation in Asia is
important to foster development of new drugs appropri-
ate for this population. Recently completed phase II
trials of new treatments are described below and
ongoing phase II and III trials of targeted therapies in
HCC are reviewed in Table 1.
The combination of sorafenib and chemotherapy has
been investigated in phase II trials. A randomized phase
II trial found superior outcomes with the combination
of sorafenib plus doxorubicin compared to placebo plus
doxorubicin [57]. Median progression-free and overall
survival times were 6.9 months and 13.8 months in the
sorafenib arm compared to 2.8 months and 6.5 months
in the placebo arm, respectively. The combination was
associated with a 21% incidence of left ventricular dys-
function, though mostly of grade 1 or 2 severity. The
SECOX trial evaluated sorafenib plus capecitabine and
oxaliplatin [58]. Response was observed in 14% with
stable disease in 61%. Median time to progression (TTP)
was 7.1 months and median survival was 10.2 months.
Toxicities included HFSR, diarrhea, and neutropenia.
When sorafenib was paired with metronomic tegafur/
uracil (UFT; 125 mg/m
2 twice daily), the combination
led to overall response and stable disease rates of 6%
and 51%, respectively [59]. Median progression-free sur-
vival was 3.7 months and median survival was 7.4
months. The most common grade 3 or 4 adverse events
were fatigue (15%), HFSR (9%), and bleeding (8%).
Sunitinib has been evaluated at various doses and
schedules. The SAKK 77/06 trial utilized sunitinib 37.5
mg/day continuously in 45 Swiss patients [60]. Median
progression-free survival (PFS) was 2.8 months and
median survival was 9.3 months. The most frequent
grade 3/4 toxicities were fatigue in 24% and thrombocy-
topenia in 18%. Two US studies evaluated sunitinib 37.5
mg daily for 4 weeks every 6 weeks [61,62]. Response
rates were 3%-6% and stable disease rates were 35%-
47%. One study reported PFS and survival; median PFS
was 4.0 months and median survival was 9.9 months.
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Study Name
Clinicaltrials.gov
Identifier
Phase Intervention Setting Location
Advanced Disease
Targeted Agents With Cytotoxic Therapy
NCT00832637 II Erlotinib + gemcitabine + oxaliplatin Prior systemic therapy allowed US
HOG GI06-101
NCT00532441
II Erlotinib + docetaxel Third-line or less US
NCT00384800 II Thalidomide + tegafur/uracil No prior chemotherapy Taiwan
NCT00519688 II Thalidomide + tegafur/uracil No prior chemotherapy Taiwan
NCT00862082 I/II Sorafenib + PR104
Sorafenib
First-line US, Asia
Anti-VEGF Agents as Monotherapy
BRISK
NCT00858871
III Brivanib + placebo
Sorafenib + placebo
First-line International
NCT00825955 III Brivanib + placebo
BSC + placebo
Sorafenib failure International
NCT00699374 III Sunitinib
Sorafenib
First-line International
NCT00247676 II Sunitinib First-line France, Korea, Taiwan
Other Targeted Agents as Monotherapy
NCT00225290 III Thalidomide
Placebo
Any line
Poor liver reserve
Taiwan
NCT00033462 II Erlotinib First- or second-line US
NCT00077441 II Bortezomib First-line US, Australia, Korea,
HK
NCT00390195 I/II Everolimus (weekly or daily) Any line Taiwan
NCT00920192 I/II Foretinib Any line Taiwan, HK
Combination Targeted Therapy
SEARCH
NCT00901901
III Sorafenib + erlotinib Sorafenib First-line International
NCT00881751 II Erlotinib + bevacizumab Sorafenib First-line US
NCT00365391 II Erlotinib + bevacizumab First- or second-line US
TCOGP-1209
NCT00971126
I/II Thalidomide + sorafenib First-line Taiwan
NCT00828594 I/II Everolimus + sorafenib Placebo +
sorafenib
First-line International
NCT00791544 I/II AVE1642* +/- sorafenib or erlotinib Any line France
Earlier-stage Disease
STORM
NCT00692770
III Sorafenib
Placebo
Adjuvant (post-resection or -local ablation) International
BRISK-TA
NCT00908752
III Brivanib + TACE
Placebo + TACE
BCLC B International
NCT00921531 III Thalidomide + TACE
TACE
BCLC A-B China
NCT00728078 II/III Thalidomide, low dose Adjuvant (post-RFA) China
START
NCT00990860
II Sorafenib + TACE BCLC B Taiwan
NCT00855218 II Sorafenib + TACE
Placebo + TACE
BCLC B International
COTSUN
NCT00919009
II Sorafenib + TACE TNM III/IVa Korea
NCT00576199 II Bevacizumab Pre- and Post-TACE HK
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elevated liver function tests. A study in Europe and Asia
that evaluated high-dose sunitinib (50 mg daily for 4
weeks every 6 weeks) found similar response and stable
disease rates but higher toxicity with four grade 5 events
[63].
Other multiple receptor tyrosine kinase inhibitors that
target VEGF under investigation include brivanib, linifa-
nib (formerly ABT-869), vandetanib, and pazopanib. Bri-
vanib inhibits VEGF and fibroblast growth factor; a
phase II trial showed median survival of 10 months in
treatment-naive patients [64] and a 58% stable disease
rate in patients who failed one prior antiangiogenic ther-
a p y[ 6 5 ] .T h em o s tf r e q u e n tg r a d e3 / 4t o x i c i t i e sw e r e
hyponatremia (41%), fatigue (16%), and AST elevation
(19%) [64]. Linifanib inhibits VEGF and PDGF receptor
tyrosine kinases. A phase II study (n = 44; 84% treat-
ment-naïve) showed a response rate of 7%, median PFS
of 3.7 months and median survival of 9.3 months [66].
Toxicities are consistent with anti-VEGF agents. A
phase II, placebo-controlled study of vandetanib, which
targets VEGFR, EGFR, and RET signaling, showed activ-
ity in HCC but failed to meet its primary endpoint of
tumor stabilization in a Taiwanese trial [67]. A phase I
dose-ranging study of pazopanib, which inhibits VEGF,
PDGF, and c-kit, showed evidence of activity [68].
Phase II trials of erlotinib plus bevacizumab are pro-
mising. In 16 previously untreated patients, the combi-
nation led to a median TTP of 2.3 months and median
survival of 13.7 months [69]. In 40 patients, 73% of
whom were previously untreated, the response rate was
25%, median PFS was 9.0 months, and median survival
was 15.7 months [70]. In 58 patients, 76% of whom
were previously untreated, median PFS times were 8.8
months in patients with no prior therapy, 7.9 months in
patients previously treated with sorafenib, and 6.6
months in those previously treated with therapy other
than sorafenib [71]. Corresponding median survival
times were 15.6 months, 13.3 months, and 14.4 months.
In all studies, adverse events were consistent with the
individual drug profiles.
Asian Panel Opinions on Clinical Trial Design
In 2008, the American Association for the Study of
Liver Diseases (AASLD) published a framework for
clinical trial design in HCC [7]. During the current
expert panel meeting, participants provided their views
about clinical trial design from an Asian perspective.
These views are outlined in Table 2.
The Asian panel also provided additional insights into
clinical trial issues specific to disease stage. The panel
noted a great need for trials in resectable disease. The
panel felt that testing compounds in the adjuvant setting
before establishing efficacy in the metastatic setting is
possible, citing positive phase II adjuvant results with
muparfostat (formerly PI-88) [72] and noting the need
for effective therapies in this setting. The panel also
expressed interest in chemoprevention with sorafenib
and other agents after resection or local ablation. In
unresectable disease, especially where locoregional ther-
apy is indicated, placebo-controlled trials remain feasi-
ble, though the panel acknowledged opportunities are
limited. In this setting, it may be beneficial to limit
enrollment to patients who experience a maximal
response after TACE based on modified EASL criteria
[73]. Such a requirement would facilitate identification
of subsequent disease progression across patients. How-
ever, additional research is necessary to identify the best
clinical endpoints in this setting. Because it remains dif-
ficult to differentiate recurrent disease from a second
primary cancer, time to development of a new lesion
may be an appropriate outcome in this setting. Finally,
in the advanced/metastatic setting, the panel felt that
developing new agents in the second-line setting is
warranted.
Summary
Hepatocellular carcinoma is a disease of variable inci-
dence and etiology that is managed differently world-
wide. This expert panel has identified key areas that
need to be addressed to facilitate clinical trials in Asia.
Stratification by viral etiology is desirable within Asia
and by region in global trials. Antiviral therapy should
also be considered as a stratification factor and incorpo-
rated into HCC management in trials. The panel agreed
with AASLD that histological diagnosis is not required
for trial entry. Staging and treatment plans vary signifi-
cantly. The panel felt BCLC staging is acceptable for
trials as long as portal vein hypertension can be mea-
sured and defined with non-invasive standardized
Table 1 Ongoing Phase II/III Trials in Advanced HCC (Continued)
JLOG 0901
NCT00933816
I/II Sorafenib + fluorouracil/platinum HAI Not suitable for resection, ablation, TACE Japan
NCT00293436 I/II Erlotinib + celecoxib Adjuvant (post-resection, -TACE, or -RFA),
high-risk
US
BSC, best supportive care; ECOG, Eastern Cooperative Oncology Group; HAI, hepatic arterial infusion; HK, Hong Kong; HOG, Hoosier Oncology Group; JLOG, Japan
Liver Oncology Group; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; US, United States; VEGF, vascular endothelial growth factor
*Anti-insulin-like growth factor receptor-1 monoclonal antibody
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sensus in treatment must be sought to allow multi-
national trials and it must be recognized that first-line
sorafenib is not largely feasible in Asia. Finally, Asian
nations must be urged to participate in clinical trials,
many of which are ongoing, to advance new treatment
options in this challenging disease.
Author details
1Prince of Wales Hospital, Shatin, Hong Kong.
2National Taiwan University
Hospital, Taipei, Taiwan.
3Kyorin University Hospital, Tokyo, Japan.
4Yonsei
University, College of Medicine, Seoul, South Korea.
5Samsung Medical
Centre, Seoul, South Korea.
6GlaxoSmithKline, Singapore.
7No. 81 Hospital of
PLA, Nanjing, China.
8Zhongshan Hospital, Shanghai, China.
Authors’ contributions
All authors contributed equally to the writing of this review. All authors read
and approved the final review.
Competing interests
Junji Furuse has received honoraria from Eli Lilly, Taiho, Bayer, and Eisai, as
well as research funding from Taiho. Winnie Yeo has received honoraria
from Pfizer, AstraZeneca, Bristol Squibb Meyer, MSD, Roche and
GlaxoSmithKline as well as research funding from Novartis. Hanlim Moon
and Ee-Min Yeoh are full-time employees of GlaxoSmithKline and hold
employee-restricted shares not exceeding GBP 15,000.
Received: 10 June 2010 Accepted: 10 November 2010
Published: 10 November 2010
References
1. Parkin D, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer
J Clin 2005, 55:74-108.
2. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence,
mortality, and prevalence across five continents: defining priorities to
reduce cancer disparities in different geographic regions of the world. J
Clin Oncol 2006, 24:2137-2150.
3. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS, for the Organizing
Committee of the Japan-Korea Liver Symposium (JKLS): Epidemiology of
hepatocellular carcinoma in Japan and Korea. Oncology 2008, 75(Suppl
1):13-16.
4. Donato F, Boffetta P, Puoti M: A meta-analysis of epidemiological studies
on the combined effect of hepatitis B and C virus infections in causing
hepatocellular carcinoma. Int J Cancer 1998, 75:347-354.
5. Mathurin P, Rixe O, Carbonell N, et al: Review article: overview of medical
treatments in unresectable hepatocellular carcinoma - an impossible
meta-analysis? Aliment Pharmacol Ther 1998, 12:111-126.
6. Llovet JM, Ricci S, Mazzaferro V, for the SHARP Investigators Study Group,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008,
359:378-390.
7. Llovet JM, Di Bisceglie AM, Bruix J, Panel of Experts in HCC-Design Clinical
Trials, et al: Design and endpoints of clinical trials in hepatocellular
carcinoma. J Natl Cancer Inst 2008, 100:698-711.
8. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in
the United States. N Engl J Med 1999, 340:745-750.
Table 2 Eastern Asian Panel’s Opinions on Clinical Trial Design Aspects
Design Aspect Panel Opinion
Patient Population
Diagnosis ￿ Agree with AASLD recommendations[7] - pathological confirmation OR noninvasive criteria per AASLD guidelines
Target population ￿ BCLC stage is acceptable, but clinical protocols must account for portal vein involvement and liver function
￿ Treatment options for CP B/C are needed; CP B/C (ECOG PS 0 only) is an ideal population to study in advanced/metastatic HCC
Liver function ￿ Agree with AASLD recommendations[7]; however, trials should separately include and/or evaluate patients based on presence
of cirrhosis or liver function grade.
Stratification ￿ Stratification by viral etiology is important in trials conducted within Eastern Asia
￿ Stratification by use of antivirals should also be considered
￿ Protocols should standardize antiviral therapy and include appropriate monitoring parameters
Treatment
Control arm for
RCTs
￿ Heterogeneity in TACE/TAE practices must be addressed
￿ Placebo-controlled trials are feasible in unresectable disease, especially for those in whom locoregional therapy is indicated,
pending maturity of post-TACE sorafenib data
￿ AASLD recommendation for sorafenib as comparator in advanced disease [7] is not necessarily reflective of real-world use in
Eastern Asia at this time due to high cost and intolerable side effects
Phase-specific Clinical Trial Recommendations
Phase I ￿ Consider conducting Asia-specific phase I trials due to the potential for PK/PD differences between Asian and Western
populations; however, Asian phase I trials may not be necessary for all targeted agents
￿ Population
￿ CP-A or CP score up to 7-8 (subgroup of CP-B) would be feasible for standard phase I trials
￿ CP-B with score 8-9 and CP-C could be enrolled in phase I trials testing agents at lower doses
Phase II ￿ For first-line studies in advanced HCC, AASLD recommendation for sorafenib [7] is not necessarily reflective of real-world use in
Eastern Asia at this time due to high cost and intolerable side effects
￿ Agents demonstrated effective for second-line use in phase II trials (not necessarily phase III trials) can be compared to
sorafenib in first-line studies
Phase III ￿ OS endpoint will soon no longer be appropriate in advanced disease with the introduction of multiple lines of therapies; PFS
may be a surrogate but it is necessary to evaluate correlation with OS (ie, as what was done in colorectal cancer)
￿ In unresectable disease, the most appropriate endpoint is unknown due to difficulty distinguishing recurrence from second
primary in the liver and unreliability of RECIST; time to development of new lesion is a possible endpoint
￿ Non-inferiority trials are acceptable if new agents have potential for less toxicity
AASLD, American Association for the Study of Liver Diseases; BCLC, Barcelona Clinic Liver Cancer; CP, Child-Pugh; OS, overall survival; PFS, progression-free
survival; PK/PD - pharmacokinetic/pharmacodynamic; RCT, randomized controlled trial; RECIST, Response Evaluation Criteria in Solid Tumors; TACE/TAE,
transarterial chemoembolization/transarterial embolization
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